Pfizer, Inc. (PFE) Shares Bought by Factory Mutual Insurance Co.
Factory Mutual Insurance Co. increased its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,935,897 shares of the biopharmaceutical company’s stock after purchasing an additional 60,000 shares during the quarter. Pfizer makes up 1.1% of Factory Mutual Insurance Co.’s portfolio, making the stock its 25th biggest holding. Factory Mutual Insurance Co.’s holdings in Pfizer were worth $98,617,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the stock. Stock Yards Bank & Trust Co. grew its position in shares of Pfizer by 0.7% during the second quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock worth $4,159,000 after purchasing an additional 832 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Pfizer during the second quarter worth about $534,000. First Command Bank grew its position in shares of Pfizer by 131.5% during the second quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock worth $804,000 after purchasing an additional 13,596 shares in the last quarter. Beacon Financial Group grew its position in shares of Pfizer by 2.3% during the second quarter. Beacon Financial Group now owns 228,070 shares of the biopharmaceutical company’s stock worth $7,670,000 after purchasing an additional 5,027 shares in the last quarter. Finally, Stillwater Capital Advisors LLC grew its position in shares of Pfizer by 1.6% during the second quarter. Stillwater Capital Advisors LLC now owns 372,131 shares of the biopharmaceutical company’s stock worth $12,500,000 after purchasing an additional 5,876 shares in the last quarter. Hedge funds and other institutional investors own 69.00% of the company’s stock.
Several analysts recently issued reports on PFE shares. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. UBS AG reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research report on Wednesday, September 6th. Finally, ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $37.83.
In related news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last 90 days. Company insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (PFE) traded up 1.69% during midday trading on Wednesday, hitting $36.05. The company had a trading volume of 11,009,800 shares. The company has a market capitalization of $214.40 billion, a PE ratio of 26.37 and a beta of 1.00. The company has a 50-day moving average of $33.78 and a 200-day moving average of $33.53. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.21.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.64 earnings per share. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were given a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.61%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.